Testing the Addition of Chemotherapy Drug, Cisplatin, to Usual Radiation Therapy for Patients with Head and Neck Cancer

Overview

The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.

Description

Participants will be assigned to receive either radiation therapy, or radiation therapy along with cisplatin. Both groups will receive treatment for 6 weeks with the doctor following their condition for 10 years after treatment.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions: Head and Neck Cancer
  • Age: Between 18 Years - 100 Years
  • Gender: Male or Female

Individuals at least 18 years of age with squamous cell carcinoma of the head/neck, that has been surgically removed.

Individuals with recurrent disease or multiple primaries will not be eligible.

Women who are pregnant or breastfeeding will not be eligible.

Updated on 20 Nov 2022 . Study ID: NCT02734537

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center